Xi Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xi Liu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chuanpeng Wang1 shared publication
- Guiyuan Lv
College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication - Jian-Li Gao
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, China
1 shared publication - Jinguo Cheng1 shared publication
- Jingwen Chang1 shared publication
Kai He
School of Medicine, The First Affiliated Hospital Zhejiang University Hangzhou China
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e96654
Explainable Machine Learning for Predicting Major Adverse Renal and Cardiovascular Events in Acute Myocardial Infarction With Chronic Kidney Disease: Algorithm Development and Validation
Background: Major adverse renal and cardiovascular events (MARCE) have been proposed as a comprehensive end point reflecting both cardiac and renal outcomes in patients with acute myocardial infarction (AMI) and chronic kidney disease (CKD). However, existing prediction tools lack accuracy and generalizability for this high-risk population. Objective: This study aimed to develop and externally validate explainable machine learning models and a nomogram for predicting in-hospital MARCE among patients with AMI and CKD. Methods: We enrolled patients with AMI and CKD who underwent emergency treatment at the First Affiliated Hospital of Wenzhou Medical University as the discovery cohort and those at Wenzhou TCM (traditional Chinese medicine) Hospital of Zhejiang Chinese Medical University as the external validation cohort. Clinical features, including demographic details, comorbidities, laboratory results, echocardiography measurements, procedural details, and medication parameters, were collected for all participants. Important variables were selected using least absolute shrinkage and selection operator regression in the training set. We developed extreme gradient boosting (XGBoost), random forest, decision tree, and logistic regression (LR) models and evaluated their discrimination, calibration, and classification metrics in the hold-out test set and external cohort. Results: In the training set, we identified 6 important variables (Killip class, lactate, estimated glomerular filtration rate, use of diuretics, use of beta-blockers, and use of renin-angiotensin system inhibitors). In the test set, model discrimination was comparable across XGBoost (area under the receiver operating characteristic curve [AUC] 0.882, 95% CI 0.816-0.947), LR (AUC 0.875, 95% CI 0.799-0.950), and random forest (AUC 0.870, 95% CI 0.800-0.940), while decision tree showed lower performance (AUC 0.814, 95% CI 0.720-0.886). Shapley additive explanations (SHAP) values illustrated both global and individual feature contributions in the XGBoost model. A nomogram based on LR achieved an AUC of 0.873 (95% CI 0.714-0.926) in external validation. Conclusions: Our study identified 6 important predictors and provided a series of prediction models to enhance risk stratification of MARCE for patients with AMI and CKD. These models might aid in stratifying risk and choosing appropriate therapeutic strategies in the management of patients with AMI and CKD.
- 23 October 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e96654
Open AccessExplainable Machine Learning for Predicting Major Adverse Renal and Cardiovascular Events in Acute Myocardial Infarction With Chronic Kidney Disease: Algorithm Development and Validation
Background: Major adverse renal and cardiovascular events (MARCE) have been proposed as a comprehensive end point reflecting both cardiac and renal outcomes in patients with acute myocardial infarction (AMI) and chronic kidney disease (CKD). However, existing prediction tools lack accuracy and generalizability for this high-risk population. Objective: This study aimed to develop and externally validate explainable machine learning models and a nomogram for predicting in-hospital MARCE among patients with AMI and CKD. Methods: We enrolled patients with AMI and CKD who underwent emergency treatment at the First Affiliated Hospital of Wenzhou Medical University as the discovery cohort and those at Wenzhou TCM (traditional Chinese medicine) Hospital of Zhejiang Chinese Medical University as the external validation cohort. Clinical features, including demographic details, comorbidities, laboratory results, echocardiography measurements, procedural details, and medication parameters, were collected for all participants. Important variables were selected using least absolute shrinkage and selection operator regression in the training set. We developed extreme gradient boosting (XGBoost), random forest, decision tree, and logistic regression (LR) models and evaluated their discrimination, calibration, and classification metrics in the hold-out test set and external cohort. Results: In the training set, we identified 6 important variables (Killip class, lactate, estimated glomerular filtration rate, use of diuretics, use of beta-blockers, and use of renin-angiotensin system inhibitors). In the test set, model discrimination was comparable across XGBoost (area under the receiver operating characteristic curve [AUC] 0.882, 95% CI 0.816-0.947), LR (AUC 0.875, 95% CI 0.799-0.950), and random forest (AUC 0.870, 95% CI 0.800-0.940), while decision tree showed lower performance (AUC 0.814, 95% CI 0.720-0.886). Shapley additive explanations (SHAP) values illustrated both global and individual feature contributions in the XGBoost model. A nomogram based on LR achieved an AUC of 0.873 (95% CI 0.714-0.926) in external validation. Conclusions: Our study identified 6 important predictors and provided a series of prediction models to enhance risk stratification of MARCE for patients with AMI and CKD. These models might aid in stratifying risk and choosing appropriate therapeutic strategies in the management of patients with AMI and CKD.
- Open Access
- 9 June 2022
- Published by Wiley in FEBS Open Bio
- Vol. 12 (7) , 1268-1285
G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors
There are two types of abnormal hematopoiesis in solid tumor occurrence and treatment: pathological hematopoiesis, and myelosuppression induced by radiotherapy and chemotherapy. In this review we primarily focus on the abnormal pathological hematopoietic differentiation in cancer induced by tumor‐released granulocyte colony‐stimulating factor (G‐CSF) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). As key factors in hematopoietic development, G‐CSF/GM‐CSF are well‐known facilitators of myelopoiesis and mobilization of hematopoietic stem cells (HSCs). In addition, these two cytokines can also promote or inhibit tumors, dependent on tumor type. In multiple cancer types, hematopoiesis is greatly enhanced and abnormal lineage differentiation is induced by these two cytokines. Here, dysregulated hematopoiesis induced by G‐CSF/GM‐CSF in solid tumors and its mechanism are summarized, and the prognostic value of G‐CSF/GM‐CSF‐associated dysregulated hematopoiesis for tumor metastasis is also briefly highlighted.
- 9 June 2022
- Published by Wiley in FEBS Open Bio
- Vol. 12 (7) , 1268-1285
Open AccessG‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors
There are two types of abnormal hematopoiesis in solid tumor occurrence and treatment: pathological hematopoiesis, and myelosuppression induced by radiotherapy and chemotherapy. In this review we primarily focus on the abnormal pathological hematopoietic differentiation in cancer induced by tumor‐released granulocyte colony‐stimulating factor (G‐CSF) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). As key factors in hematopoietic development, G‐CSF/GM‐CSF are well‐known facilitators of myelopoiesis and mobilization of hematopoietic stem cells (HSCs). In addition, these two cytokines can also promote or inhibit tumors, dependent on tumor type. In multiple cancer types, hematopoiesis is greatly enhanced and abnormal lineage differentiation is induced by these two cytokines. Here, dysregulated hematopoiesis induced by G‐CSF/GM‐CSF in solid tumors and its mechanism are summarized, and the prognostic value of G‐CSF/GM‐CSF‐associated dysregulated hematopoiesis for tumor metastasis is also briefly highlighted.